Skip to main content Skip to main navigation menu Skip to site footer

Advances in understanding and managing diabetic kidney disease: An updated review

Elmukhtar Habas Hamad General Hospital, Open Libyan University, Doha, Qatar http://orcid.org/0000-0002-7754-8993
Amnna Rayani Tripoli Pediatric Hospital, Open Libyan University, Tripoli, Libya https://orcid.org/0009-0005-5161-6555
Aml Habas Tripoli Pediatric Hospital, Open Libyan University, Tripoli, Libya https://orcid.org/0009-0000-1862-2711
Kalifa Farfar Hamad General Hospital, Doha, Qatar https://orcid.org/0009-0005-9396-5251
Eshrak Habas Tripoli Central Hospital, Tripoli University, Tripoli-Libya https://orcid.org/0009-0004-1044-7110
Khaled Alarbi Hamad General Hospital, Doha, Qatar https://orcid.org/0009-0006-2952-1282
Ala Habas Tripoli Central Hospital, Tripoli University, Tripoli-Libya https://orcid.org/0009-0003-6488-8133
Elmehdi Errayes Hamad General Hospital, Doha, Qatar http://orcid.org/0009-0001-9126-1585
Gamal Alfitori Hamad General Hospital, Doha, Qatar https://orcid.org/0000-0003-2758-7780

DOI: https://doi.org/10.31450/ukrjnd.1(85).2025.09

Keywords: diabetic kidney disease, diabetic nephropathy, pathogenesis, treatment, prevention.

Abstract

Chronic kidney disease (CKD) and end-stage kidney disease (ESKD) are common complications of diabetes. Proteinuria is an early indicator of glomerular basement membrane damage caused by diabetes, leading to diabetic kidney disease (DKD). Edema, hypoproteinemia, and proteinuria are common characteristics of DKD. Blood sugar and blood pressure control, along with early detection, are the primary strategies for preventing DKD and slowing its progression.

This review examines and updates the epidemiology, pathogenesis, and prevention of DKD. Various keywords and phrases are used to search Google, EMBASE, PubMed, Scopus, and Google Scholar for the most recent articles published from January 2023 to December 2024.

Despite advancements in understanding DKD pathogenesis and the development of novel therapies, the disease remains highly prevalent with poor outcomes. The pathophysiology is still not fully understood, leading to gaps in prevention and treatment strategies. Therefore, this review aims to explore these gaps and propose potential new therapies and future research directions.

Downloads

Download data is not yet available.

References

Varghese RT JI. Diabetic Nephropathy. In: StatPearls. Treasure Island (FL): StatPearls Publishing. [Internet]; 2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK534200/.

Tang SC, Chan GC, Lai KN. Recent advances in managing and understanding diabetic nephropathy. F1000Res. 2016;5:F1000 Faculty Rev-1044. doi: 10.12688/f1000research.7693.1.

Moriya T, Yamagishi T, Matsubara M, Ouchi M. Serial renal biopsies in normo- and microalbuminuric patients with type 2 diabetes demonstrate that loss of renal function is associated with a reduction in glomerular filtration surface secondary to mesangial expans. J Diabetes Complicat. 2019;33(5):368-373. doi: 10.1016/j.jdiacomp.2019.02.002.

Gheith O, Farouk N, Nampoory N, Halim MA, Al-Otaibi T. Diabetic kidney disease: world wide difference of prevalence and risk factors. J Nephropharmacol. [Internet]. 2015;5(1):49-56. Available from: https://pubmed.ncbi.nlm.nih.gov/28197499/.

Feng XS, Farej R, Dean BB, Xia F, Gaiser A, Kong SX, et al. CKD Prevalence Among Patients With and Without Type 2 Diabetes: Regional Differences in the United States. Kidney Med. 2021;4(1):100385. doi: 10.1016/j.xkme.2021.09.003.

Alicic RZ, Rooney MT, Tuttle KR. Diabetic Kidney Disease: Challenges, Progress, and Possibilities. Clin J Am Soc Nephrol. 2017;12(12):2032-45. doi: 10.2215/CJN.11491116.

American Diabetes Association Professional Practice Committee. 11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 ;45(1):175-184. doi: 10.2337/dc22-S011.

Sugahara M, Pak WLW, Tanaka T, Tang SCW, Nangaku M. Update on diagnosis, pathophysiology, and management of diabetic kidney disease. Nephrology (Carlton). 2021;26(6):491-500 doi: 10.1111/nep.13860.

Diabetes Canada Clinical Practice Guidelines Expert Committee; McFarlane P, Cherney D, Gilbert RE, Senior P. Chronic Kidney Disease in Diabetes. Can J Diabetes. 2018;42(1):201-209. doi: 10.1016/j.jcjd.2017.11.004.

Kengne AP, Sobngwi E, Echouffo-Tcheugui JB, Mbanya JC. New insights on diabetes mellitus and obesity in Africa-Part 2: prevention, screening and economic burden. Heart. 2013;99(15):1072-7. doi: 10.1136/heartjnl-2013-303773.

IDF Diabetes Atlas. Tenth edition. [Internet]. 2021:137. Available from: https://diabetesatlas.org/idfawp/resourcefiles/2021/07/IDF_Atlas_10th_Edition_2021.pdf.

Stel VS, de Jong RW, Kramer A, Andrusev AM, Baltar JM, Barbullushi M, et al. Supplemented ERA-EDTA Registry data evaluated the frequency of dialysis, kidney transplantation, and comprehensive conservative management for patients with kidney failure in Europe. Kidney Int. 2021 Jul;100(1):182-195. doi: 10.1016/j.kint.2020.12.010.

Claessen H, Narres M, Kvitkina T, Wilk A, Friedel H, Günster C, et al. Renal Replacement Therapy in People With and Without Diabetes in Germany, 2010-2016: An Analysis of More Than 25 Million Inhabitants. Diabetes Care. 2021;44(6):1291-9. doi: 10.2337/dc20-2477.

Klessens CQ, Woutman TD, Veraar KA, Zandbergen M, Valk EJ, Rotmans JI, et al. An autopsy study suggests that diabetic nephropathy is underdiagnosed. Kidney Int. 2016;90(1):149-56. doi: 10.1016/j.kint.2016.01.023.

Al-Zahrani N, AlSwat HK, AlQarni AM, Alzahrani SS, Boubshait LA, Alassaf LA, et al. Prevalence and Risk Factors of Diabetic Nephropathy Among Saudi Type-1 Diabetic Patients in Taif City, Saudi Arabia. Diabetes Metab Syndr Obes. 2023;16:3609-3616. doi: 10.2147/DMSO.S432700.

Awad SF, A Toumi A, A Al-Mutawaa K, A Alyafei S, A Ijaz M, A H Khalifa S, et al. Type 2 diabetes epidemic and key risk factors in Qatar: a mathematical modeling analysis. BMJ Open Diabetes Res Care. 2022;10(2):e002704. doi: 10.1136/bmjdrc-2021-002704.

Awad SF, O’Flaherty M, Critchley J, Abu-Raddad LJ. Forecasting the burden of type 2 diabetes mellitus in Qatar to 2050: A novel modeling approach. Diabetes Res Clin Pract. 2018;137:100-108. doi: 10.1016/j.diabres.2017.11.015.

Fan JZ , Wang R. Non-diabetic renal disease in patients with type 2 diabetes: a single centre study. Intern Med J. 2018;48(4):451-456. doi: 10.1111/imj.13708.

AlSahow A. Demographics and key clinical characteristics of hemodialysis patients from the gulf cooperation council (GCC) participating in DOPPS. Nephrol Dialysis Transplant. 2016;31:i279–i297. doi: 10.1093/ndt/gfw175.29.

Pavkov ME, Bennett PH, Knowler WC, Krakoff J, Sievers ML, Nelson RG. Effect of youth-onset type 2 diabetes mellitus on incidence of end-stage renal disease and mortality in young and middle-aged Pima Indians. JAMA. 2006;296(4):421-6. doi: 10.1001/jama.296.4.421.

Noubiap JJ, Naidoo J, Kengne AP. Diabetic nephropathy in Africa: A systematic review. World J Diabetes. 2015;6(5):759-73. doi: 10.4239/wjd.v6.i5.759.

Abd ElHafeez S, Bolignano D, D’Arrigo G, Dounousi E, Tripepi G, Zoccali C. Prevalence and burden of chronic kidney disease among the general population and high-risk groups in Africa: a systematic review. BMJ Open. 2018;8(1):e015069. doi: 10.1136/bmjopen-2016-015069.

Sinha SK, Nicholas SB. Pathomechanisms of Diabetic Kidney Disease. J Clin Med. 2023;12(23):7349. doi: 10.3390/jcm12237349.

Chen W, Zhang M, Guo Y, Wang Z, Liu Q, Yan R, et al. The Profile and Function of Gut Microbiota in Diabetic Nephropathy. Diabetes Metab Syndr Obes. 2021;14:4283-4296. doi: 10.2147/DMSO.S320169.

Wu X, Zhao L, Zhang Y, Li K, Yang J. The role and mechanism of the gut microbiota in the development and treatment of diabetic kidney disease. Front Physiol. 2023;14:1166685. doi: 10.3389/fphys.2023.1166685.

Zhang L, Wang Z, Zhang X, Zhao L, Chu J, Li H, et al. Alterations of the Gut Microbiota in Patients with Diabetic Nephropathy. Microbiol Spectr. 2022 ;10(4):e0032422. doi: 10.1128/spectrum.00324-22.

Lin YC, Chang YH, Yang SY, Wu KD, Chu TS. Update of pathophysiology and management of diabetic kidney disease. J Formos Med Assoc. 2018;117(8):662-75. doi: 10.1016/j.jfma.2018.02.007.

Samsu N. Diabetic Nephropathy: Challenges in Pathogenesis, Diagnosis, and Treatment. Biomed Res Int. 2021;2021:1497449. doi: 10.1155/2021/1497449.

Oh SW, Yang JH, Kim MG, Cho WY, Jo SK. Renal hyperfiltration as a risk factor for chronic kidney disease: A health checkup cohort study. PLoS One. 2020;15(9):e0238177. doi: 10.1371/journal.pone.0238177.

Wu T, Ding L, Andoh V, Zhang J, Chen L. The Mechanism of Hyperglycemia-Induced Renal Cell Injury in Diabetic Nephropathy Disease: An Update. Life (Basel). 2023;13(2):539. doi: 10.3390/life13020539.

Maezawa Y, Takemoto M, Yokote K. Cell biology of diabetic nephropathy: roles of endothelial cells, tubulointerstitial cells and podocytes. J Diabetes Investig. 2015;6(1):3–15. doi: 10.1111/jdi.12255.

Han W, Zheng Q, Zhang Z, Wang X, Gao L, Niu D, et al. Association of the podocyte phenotype with extracapillary hypercellularity in patients with diabetic kidney disease. J Nephrol. 2024;37(8):2209-22. doi: 10.1007/s40620-024-01981-0.

Watanabe K, Sato E, Mishima E, Miyazaki M, Tanaka T. What’s New in the Molecular Mechanisms of Diabetic Kidney Disease: Recent Advances. Int. J. Mol. Sci. 2022;24:570. doi: 10.3390/ijms24010570.

Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016 ;375(4):323-34. doi: 10.1056/NEJMoa1515920.

Tonneijck L, Muskiet MH, Smits MM, van Bommel EJ, Heerspink HJ, van Raalte DH, et al. Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment. J Am Soc Nephrol. 2017;28(4):1023-39. doi: 10.1681/ASN.2016060666.

Mende CW, Samarakoon R, Higgins PJ. Mineralocorticoid Receptor-Associated Mechanisms in Diabetic Kidney Disease and Clinical Significance of Mineralocorticoid Receptor Antagonists. Am J Nephrol. 2023;54(1-2):50-61. doi: 10.1159/000528783.

Kataoka H, Nitta K, Hoshino J. Glomerular hyperfiltration and hypertrophy: an evaluation of maximum values in pathological indicators to discriminate “diseased” from “normal”. Front Med (Lausanne). 2023;10:1179834. doi: 10.3389/fmed.2023.1179834.

Leoncini G, Viazzi F, De Cosmo S, Russo G, Fioretto P, Pontremoli R. Blood pressure reduction and RAAS inhibition in diabetic kidney disease: therapeutic potentials and limitations. J Nephrol. 2020;33(5):949-63. doi: 10.1007/s40620-020-00803-3.

Pelle MC, Provenzano M, Busutti M, Porcu CV, Zaffina I, Stanga L, et al. Up-Date on Diabetic Nephropathy. Life (Basel). 2022;12(8):1202. doi: 10.3390/life12081202.

Premilovac D, Attrill E, Rattigan S, Richards SM, Kim J, Keske MA. Acute, local infusion of angiotensin II impairs microvascular and metabolic insulin sensitivity in skeletal muscle. Cardiovasc Res. 2019;115(3):590-601. doi: 10.1093/cvr/cvy225.

Hallow KM, Gebremichael Y, Helmlinger G, Vallon V. Primary proximal tubule hyperreabsorption and impaired tubular transport counterregulation determine glomerular hyperfiltration in diabetes: a modeling analysis. Am J Physiol Renal Physiol. 2017;312(5):F819-F835. doi: 10.1152/ajprenal.00497.2016.

Wang H, Romero CA, Masjoan Juncos JX, Monu SR, Peterson EL, Carretero OA. Effect of salt intake on afferent arteriolar dilatation: role of connecting tubule glomerular feedback (CTGF). Am J Physiol Renal Physiol. 2017;313(6):1209-15. doi: 10.1152/ajprenal.00320.2017.

Koh ES, Kim GH, Chung S. Intrarenal Mechanisms of Sodium-Glucose Cotransporter-2 Inhibitors on Tubuloglomerular Feedback and Natriuresis. Endocrinol Metab (Seoul). 2023;38(4):359-372. doi: 10.3803/EnM.2023.1764.

Yoshimoto T, Furuki T, Kobori H, Miyakawa M, Imachi H, Murao K, Nishiyama A. Effects of sodium-glucose cotransporter 2 inhibitors on urinary excretion of intact and total angiotensinogen in patients with type 2 diabetes. J Investig Med. 2017;65(7):1057-61. doi: 10.1136/jim-2017-000445.

Chen YY, Chen DQ, Chen L, Liu JR, Vaziri ND, Guo Y, et al. Microbiome-metabolome reveals the contribution of gut-kidney axis on kidney disease. J Transl Med. 2019;17(1):5. doi: 10.1186/s12967-018-1756-4.

Mosterd CM, Kanbay M, van den Born BJH, van Raalte DH, Rampanelli E. Intestinal microbiota and diabetic kidney diseases: the Role of microbiota and derived metabolites inmodulation of renal inflammation and disease progression. Best Pract Res Clin Endocrinol Metab. 2021;35(3):101484. doi: doi: 10.1016/j.beem.2021.101484.

Nagase N, Ikeda Y, Tsuji A, Kitagishi Y, Matsuda S. Efficacy of probiotics on the modulation of gut microbiota in the treatment of diabetic nephropathy. World J Diabetes. 2022;13(3):150-160. doi: 10.4239/wjd.v13.i3.150.

Xiong Y, Zhou L. The Signaling of Cellular Senescence in Diabetic Nephropathy. Oxid Med Cell Longev. 2019;2019:7495629. doi: 10.1155/2019/7495629.

Araújo LS, Torquato BGS, da Silva CA, Dos Reis Monteiro MLG, Dos Santos Martins ALM, et al. Renal expression of cytokines and chemokines in diabetic nephropathy. BMC Nephrol. 2020;21(1):308. doi: 10.1186/s12882-020-01960-0.

Salti T, Khazim K, Haddad R, Campisi-Pinto S, Bar-Sela G, Cohen I. Glucose Induces IL-1α-Dependent Inflammation and Extracellular Matrix Proteins Expression and Deposition in Renal Tubular Epithelial Cells in Diabetic Kidney Disease. Front Immunol. 2020. 11:1270. doi: 10.3389/fimmu.2020.01270.

Milas O, Gadalean F, Vlad A, Dumitrascu V, Velciov S, Gluhovschi C, et al. Pro-inflammatory cytokines are associated with podocyte damage and proximal tubular dysfunction in the early stage of diabetic kidney disease in type 2 diabetes mellitus patients. J Diabetes Complicat. 2020;34(2):107479. doi: 10.1016/j.jdiacomp.2019.107479.

Sangoi MB, de Carvalho JA, Tatsch E, Hausen BS, Bollick YS, Londero SW, et al. Urinary inflammatory cytokines as indicators of kidney damage in type 2 diabetic patients. Clin Chim Acta. 2016;460:178-83. doi: 10.1016/j.cca.2016.06.028.

McGeough MD, Wree A, Inzaugarat ME, Haimovich A, Johnson CD, Peña CA, et al. TNF regulates transcription of NLRP3 inflammasome components and inflammatory molecules in cryopyrinopathies. J Clin Invest. 2017;127(12):4488-97. doi: 10.1172/JCI90699.

Coca SG, Nadkarni GN, Huang Y, Moledina DG, Rao V, Zhang J, et al. Plasma Biomarkers and Kidney Function Decline in Early and Established Diabetic Kidney Disease. J Am Soc Nephrol. 2017;28(9):2786-93. doi: 10.1681/ASN.2016101101.

Bonner R, Albajrami O, Hudspeth J, Upadhyay A. Diabetic Kidney Disease. Prim Care. 2020;47(4):645-59. doi: 10.1016/j.pop.2020.08.004.

Flyvbjerg A. The role of the complement system in diabetic nephropathy. Nat Rev Nephrol. 2017;13(5):311-8. doi: 10.1038/nrneph.2017.31.

Zhang Y, Jin D, Kang X, Zhou R, Sun Y, Lian F, Tong X. Signaling Pathways Involved in Diabetic Renal Fibrosis. Front Cell Dev Biol. 2021;9:696542. doi: 10.3389/fcell.2021.696542.

Kourtidou C, Tziomalos K. The Role of Histone Modifications in the Pathogenesis of Diabetic Kidney Disease. Int J Mol Sci. 2023;24(6):6007. doi: 10.3390/ijms24066007.

Majumder S, Thieme K, Batchu SN, Alghamdi TA, Bowskill BB, Kabir MG, et al. Shifts in podocyte histone H3K27me3 regulate mouse and human glomerular disease. J Clin Invest. 2018 Jan 2;128(1):483-99. doi: 10.1172/JCI95946.

Barton M, Yanagisawa M. Endothelin: 30 Years From Discovery to Therapy. Hypertension. 2019;74(6):1232-65. doi: 10.1161/HYPERTENSIONAHA.119.12105.

Chung EYM, Badve SV, Heerspink HJL, Wong MG. Endothelin receptor antagonists in kidney protection for diabetic kidney disease and beyond? Nephrology (Carlton). 2023;28(2):97-108. doi: 10.1111/nep.14130.

Benigni A, Buelli S, Kohan DE. Endothelin-targeted new treatments for proteinuric and inflammatory glomerular diseases: focus on the added value to anti-renin-angiotensin system inhibition. Pediatr Nephrol. 2021;36(4):763-775. doi: 10.1007/s00467-020-04518-2.

Ebefors K, Wiener RJ, Yu L, Azeloglu EU, Yi Z, et al. Endothelin receptor-A mediates degradation of the glomerular endothelial surface layer via pathologic crosstalk between activated podocytes and glomerular endothelial cells. Kidney Int. 2019;96(4):957-70. doi: 10.1016/j.kint.2019.05.007.

Chen Y, Lee K, Ni Z, He JC. Diabetic Kidney Disease: Challenges, Advances, and Opportunities. Kidney Dis (Basel). 2020;6(4):215-25. doi: 10.1159/000506634.

Kulkarni A, Thool AR, Daigavane S. Understanding the Clinical Relationship Between Diabetic Retinopathy, Nephropathy, and Neuropathy: A Comprehensive Review. Cureus. 2024;16(3):e56674. doi: 10.7759/cureus.56674.

Fang J, Luo C, Zhang D, He Q LL. Correlation between diabetic retinopathy and diabetic nephropathy: a two-sample Mendelian randomization study. Front Endocrinol (Lausanne). 2023;14:1265711. doi: 10.3389/fendo.2023.1265711.

McGrath K, Edi R. Diabetic Kidney Disease: Diagnosis, Treatment, and Prevention. Am Fam Physician. [Internet]. 2019;99(12):751-759. Available from: https://pubmed.ncbi.nlm.nih.gov/31194487/.

ElSayed NA, Bannuru RR, Bakris G, Bardsley J, de Boer IH, Gabbay RA, et al. Diabetic Kidney Disease Prevention Care Model Development. Clin Diabetes. 2024;42(2):274-94. doi: 10.2337/cd23-0063.

Feingold KR. Dyslipidemia in Patients with Diabetes. In: Feingold KR, Anawalt B, Blackman MR, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK305900/.

Zaky A, Glastras SJ, Wong MYW, Pollock CA, Saad S. The Role of the Gut Microbiome in Diabetes and Obesity-Related Kidney Disease. Int J Mol Sci. 2021;22(17):9641. doi: 10.3390/ijms22179641.

Yang G, Wei J, Liu P, Zhang Q, Tian Y, Hou G, et al. Role of the gut microbiota in type 2 diabetes and related diseases. Metabolism. 2021;117:154712. doi: 10.1016/j.metabol.2021.154712.

Fang Y, Chen B, Gong AY, Malhotra DK, Gupta R, Dworkin LD, et al. The ketone body β-hydroxybutyrate mitigates the senescence response of glomerular podocytes to diabetic insults. Kidney Int. 2021;100(5):1037-53. doi: 10.1016/j.kint.2021.06.031.

Gulati AS, Nicholson MR, Khoruts A, Kahn SA. Fecal Microbiota Transplantation Across the Lifespan: Balancing Efficacy, Safety, and Innovation. Am J Gastroenterol. 2023;118(3):435-439. doi: 10.14309/ajg.0000000000002167.

Kootte RS, Levin E, Salojärvi J, Smits LP, Hartstra AV, Udayappan SD, et al. Improvement of Insulin Sensitivity after Lean Donor Feces in Metabolic Syndrome Is Driven by Baseline Intestinal Microbiota Composition. Cell Metab. 2017;26(4):611-619.e6. doi: 10.1016/j.cmet.2017.09.008.

Ni Y, Zheng L, Nan S, Ke L, Fu Z, Jin J. Enterorenal crosstalks in diabetic nephropathy and novel therapeutics targeting the gut microbiota. Acta Biochim Biophys Sin (Shanghai). 2022;54(10):1406-20. doi: 10.3724/abbs.2022140.

Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2020;98(4S):S1-S115. doi: 10.1016/j.kint.2020.06.019.

ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2023. Diabetes Care. 2023;46(1):191-202. doi: 10.2337/dc23-S011.

Elmukhtar Habas, Ala Habas, Islam Elzouki, Gamal Alfitori, Elmehdi Arrayes, Amnna Rayani, et al. Sodium-Glucose Cotransporter 2 Inhibitors’ Mechanism of Action and Use in Kidney Transplantation Recipients: Extended Review and Update. J Diabetes Endocrine Practice 2024;7:66–76. doi: 10.1055/s-0044-1782673.

Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. CREDENCE Trial Investigators. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019;380(24):2295-2306. doi: 10.1056/NEJMoa1811744.

Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436-46. doi: 10.1056/NEJMoa2024816.

de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, et al. Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. 2022;45(12):3075-90. doi: 10.2337/dci22-0027.

Kawanami D, Takashi Y. GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Clinical Outcomes to Mechanisms. Front Pharmacol. 2020;11:967. doi: 10.3389/fphar.2020.00967.

Hviid AVR, Sørensen CM. Glucagon-like peptide-1 receptors in the kidney: impact on renal autoregulation. Am J Physiol Renal Physiol. 2020;318(2):F443-F454. doi: 10.1152/ajprenal.00280.2019.

Ronn J, Jensen EP, Wewer Albrechtsen NJ, Holst JJ, Sorensen CM. Glucagon-like peptide-1 acutely affects renal blood flow and urinary flow rate in spontaneously hypertensive rats despite significantly reduced renal expression of GLP-1 receptors. Physiol Re. 2017;5(23):e13503. doi: 10.14814/phy2.13503.

GRADE Study Research Group; Nathan DM, Lachin JM, Balasubramanyam A, et al. Glycemia reduction in type 2 diabetes: glycemic outcomes. N Engl J Med 2022;387: 1063–74. doi: 10.1056/NEJMoa2200433.

Kristensen SL, Rørth R, Jhund PS, Docherty KF, Sattar N, Preiss D, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7(10):776-85. doi: 10.1016/S2213-8587(19)30249-9.

Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121-30. doi: 10.1016/S0140-6736(19)31149-3.

Seidu S, Lawson CA, Kunutsor SK, Khunti K, Rosano GMC. Blood pressure levels and adverse cardiovascular outcomes in heart failure: A systematic review and meta-analysis. Eur J Heart Fail. 2024;26(5):1111-24. doi: 10.1002/ejhf.3108.

Parajuli S, Arunachalam A, Swanson KJ, Aziz F, Garg N, et al. Outcomes after simultaneous kidney-pancreas versus pancreas after kidney transplantation in the current era. Clin Transplant. 2019;33(12):e13732. doi: 10.1111/ctr.13732.

Sampaio MS, Kuo HT, Bunnapradist S. Outcomes of simultaneous pancreas-kidney transplantation in type 2 diabetic recipients. Clin J Am Soc Nephrol. 2011;6(5):1198-206. doi: 10.2215/CJN.06860810.

Ventura-Aguiar P, Ruiz JC, Sequeira P, Domínguez-Gil B. Kidney-pancreas transplantation - An excellent treatment alternative for the patient with insulin-dependent diabetes and advanced chronic kidney disease. Nefrologia (Engl Ed). 2023;43(4):383-385. doi: 10.1016/j.nefroe.2022.06.009.

Hishida M, Shafi T, Appel LJ, Maruyama S, Inaguma D, Matsushita K. Lower levels of proteinuria are associated with elevated mortality in incident dialysis patients. PLoS One. 2019;14(12):e0226866. doi: 10.1371/journal.pone.0226866.

Costacou T, Orchard TJ. Cumulative Kidney Complication Risk by 50 Years of Type 1 Diabetes: The Effects of Sex, Age, and Calendar Year at Onset. Diabetes Care. 2018;41(3):426-33. doi: 10.2337/dc17-1118.

Zhang J, Wang Y, Li L, Zhang R, Guo R, Li H, et al. Diabetic retinopathy may predict the renal outcomes of patients with diabetic nephropathy. Ren Fail. 2018;40(1):243-51. doi: 10.1080/0886022X.2018.1456453.

Jiang R, Law E, Zhou Z, Yang H, Wu EQ, Seifeldin R. Clinical Trajectories, Healthcare Resource Use, and Costs of Diabetic Nephropathy Among Patients with Type 2 Diabetes: A Latent Class Analysis. Diabetes Ther. 2018;9(3):1021-36. doi: 10.1007/s13300-018-0410-8.

Rosolowsky ET, Skupien J, Smiles AM, Niewczas M, Roshan B, Stanton R, et al. Risk for ESKD in type 1 diabetes remains high despite renoprotection. J Am Soc Nephrol. 2011;22(3):545-53. doi: 10.1681/ASN.2010040354.

Helve J, Sund R, Arffman M, Harjutsalo V, Groop PH, et al. Incidence of End-Stage Renal Disease in Patients With Type 1 Diabetes. Diabetes Care. 2018;41(3):434-39. doi: 10.2337/dc17-2364.

PDF

Abstract views: 854
PDF Downloads: 333

Published

2025-02-19

How to Cite

Habas, E., Rayani, A., Habas, A., Farfar, K., Habas, E., Alarbi, K., Habas, A., Errayes, E., & Alfitori, G. (2025). Advances in understanding and managing diabetic kidney disease: An updated review. Ukrainian Journal of Nephrology and Dialysis, (1(85), 66-80. https://doi.org/10.31450/ukrjnd.1(85).2025.09

Download Citation

Issue

No 1(85) (2025): Ukrainian Journal of Nephrology and Dialysis

Section

Nephrology School

Copyright (c) 2025 Ukrainian Journal of Nephrology and Dialysis

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Most read articles by the same author(s)

Elmukhtar Habas, Amnna Rayani, Aml Habas, Gamal Afitori, Ala Habas, Kalifa Farfar, Eshrak Habas, Khaled Alarbi, Mohamed Bagi, Almehdi Errayes, Abdelrahman Hamad, Abdel-Naser Elzouki, Burden of anemia in kidney transplant patients: Epidemiology, pathophysiology, and management , Ukrainian Journal of Nephrology and Dialysis: No 2(86) (2025): Ukrainian Journal of Nephrology and Dialysis